CN101391004B - Medicine composition for treating late-stage esophageal carcinoma - Google Patents
Medicine composition for treating late-stage esophageal carcinoma Download PDFInfo
- Publication number
- CN101391004B CN101391004B CN2007101394458A CN200710139445A CN101391004B CN 101391004 B CN101391004 B CN 101391004B CN 2007101394458 A CN2007101394458 A CN 2007101394458A CN 200710139445 A CN200710139445 A CN 200710139445A CN 101391004 B CN101391004 B CN 101391004B
- Authority
- CN
- China
- Prior art keywords
- parts
- rhizoma
- treatment
- pharmaceutical composition
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicine combination for curing advanced esophageal cancer, which is composed of following materials by weight ratio: 20 to 120 parts of Herba Rabdosiae, 20 to 40 parts of dry gecko, 25 to 35 parts of subprostrate sophora, 5 to 15 parts of rhizoma pinellinae praeparata, 5 to 15 parts of Arisacma Consanguineum, 15 to 30 parts of red ginseng, 20 to 30 parts of semen astragali complanati and 20 to 30 parts of Baikal skullcap root. The medicine combination is provided with fine synergic action, the side effect is small, and the medicine combination has the functions of directly killing the cancer cells, restraining the cell period, guiding the tumour cell to be withered, restraining the forming of tumour cell, guiding the tumour cell cytoclasis gene, resisting tumour to generate and transfer, and strengthening immunity function of organism.
Description
Technical field
The present invention relates to be used for the treatment of the pharmaceutical composition of late esophagus cancer, specifically the pharmaceutical composition that is active component with natural animal and plant extract.
Background technology
The esophageal carcinoma is that common digestion is one of malignant tumor, and its mortality rate is 16.7/10 ten thousand, accounts for 21.8% of whole malignant tumor, and the people's life in its serious threat.Therapeutic Method to the esophageal carcinoma remains based on surgical operation, chemicotherapy at present.Because the early stage esophageal carcinoma lacks classical symptom, is difficult for early discovery, so most patient has belonged to late period when going to a doctor.Metastasis has often taken place in late esophagus cancer patient its carninomatosis accommodation, so 80% patient has been unsuitable for adopting operative treatment.Though and chemicotherapy can dwindle focus in recent patients in remission, there are many unsatisfactory parts in it, and is big as the toxic and side effects of putting, complication is many; Major injury normal cell tissue again in kill cancer cell; Patient's life quality is poor; Being not suitable for a year high weak patient uses or the like.For addressing these problems, the medical expert has carried out positive exploration aspect the Chinese herbal treatment esophageal carcinoma utilizing, discover that as the medical research personnel many Chinese herbal medicine have certain antitumaous effect, all have certain active anticancer such as Rabdosia rubescens, Bulbus Lycoridis Radiatae, Melia azedarach L., Folium seu Cortex Nerii, Herba Catharanthi Rosei, Folium et Ramulus Cephalotaxi, Mylabris, Venenum Bufonis, Herba Scutellariae Barbatae or the like.But regrettably, these single Chinese herbal medicine or exist toxic and side effects big or have a weak shortcoming of pharmaceutically active.At present, also have many Chinese patent medicines to be used for the treatment of late esophagus cancer clinically, but its clinical efficacy remain further to be improved.
Purpose of the present invention is exactly that a kind of pharmaceutical composition that is used for the treatment of late esophagus cancer will be provided, and its clinical efficacy is good, and toxic and side effects is little, can effectively alleviate the patient suffering, improves patient's life quality.
The object of the present invention is achieved like this:
The inventor has done further research to the anticancer pharmacologically active of many plants, and its active anticancer is not ideal enough when finding its independent application, and especially for advanced esophageal carcinoma, its curative effect is poorer.Through a large amount of clinical practice and experimentatioies, the inventor finds to distinguish the treatment theory of controlling cancer according to three, carry out screening, the combination of cancer therapy drug component from many target spots, multi-angle, 5 compositions again with strengthening the body resistance, constitute thus one evident in efficacy, compatibility is reasonable, and modern Chinese medicine medicine for preventing that can integrally-regulated organism balance.In view of the above, the inventor has finished the prescription compatibility of medicine of the present invention.
The pharmaceutical composition that is used for the treatment of late esophagus cancer provided by the present invention includes the raw material of following weight part ratio:
Rabdosia rubescens 20-120 part, Gekko Swinhonis 20-40 part, Radix Sophorae Tonkinensis 25-35 part, Rhizoma Pinelliae Preparatum 5-15 part, Rhizoma Arisaematis (processed) 5-15 part, Radix Ginseng Rubra 15-30 part, Semen Astragali Complanati 20-30 part, Radix Scutellariae 20-30 part.
Preferred weight part ratio of the present invention is:
Rabdosia rubescens 80-120 part, Gekko Swinhonis 25-30 part, Radix Sophorae Tonkinensis 25-35 part, Rhizoma Pinelliae Preparatum 5-10 part, Rhizoma Arisaematis (processed) 5-10 part, Radix Ginseng Rubra 20-30 part, Semen Astragali Complanati 25-30 part, Radix Scutellariae 25-30 part.
Contain rubescensin in the Rabdosia rubescens in the component of the present invention, it has antitumaous effect to human body esophageal carcinoma Eca-109 cell strain, human body esophageal cancer cell strain CaEs-17.Its anticancer mechanism mainly is the anabolic effect link that suppresses tumor cell DNA, promptly suppresses the process that the polymerization of nucleotide substrate forms DNA; The Radix Sophorae Tonkinensis main component is matrine, oxymatrine, its water extract has lethality to human esophagus cancer cell strain (Eca-109), and tumor cell DNA or RNA are had inhibitory action, can improve T cell ratio, strengthen or the adjustment macrophage phagocytic function, have the function that strengthening vital QI to eliminate pathogenic factors consolidates; Rhizoma Pinelliae Preparatum is inhibited to esophageal carcinoma Eca-109 cell; Rhizoma Arisaematis (processed) is inhibited to U14; But it is the Gekko Swinhonis inducing apoptosis of tumour cell, and also inhibited to tumor-blood-vessel growth; But the Semen Astragali Complanati anticancer, the effect that has certain enhancing human body immunity power simultaneously; Baicalin in the Radix Scutellariae can directly suppress the division and the hypertrophy of esophageal cancer cell; But the ginsenoside in the Radix Ginseng Rubra, ginseng polysaccharide's human body immunity improving power, but also anticancer division simultaneously, suppress tumor neovasculature generation, recover hemopoietic function of bone marrow;
The present invention screens, verifies by the multiple anticancer property of component just, make integral formula have good synergism, make it have the direct killing cancerous cell simultaneously, suppress cell cycle, inducing apoptosis of tumour cell, inhibition tumor vessel form, induce the tumor cell necrosin, stop tumor growth and transfer, the effect of enhancing human body immunity function, have improved the whole anticancer effect of medicine thus greatly.Moreover because the component that the present invention selects for use is entirely natural Chinese medicinal herb, and 5 usefulness of each component have reduced the clinical practice amount of monotaste plant medicine, thereby greatly reduce the toxic and side effects of medicine.
In order further to strengthen clinical efficacy of the present invention, in aforementioned pharmaceutical compositions, can also increase the raw material of following weight part ratio: Lentinus Edodes 20-30 part, Radix Astragali 15-25 part.
It also can be the raw material that increases following weight part ratio: Ganoderma spore oil 20-30 part, Fructus Lycii 15-25 part, Rhizoma Polygonati 20-30 part.
The Radix Astragali among the present invention, Lentinus Edodes, Ganoderma spore oil (commercially available acquisition), Fructus Lycii, Rhizoma Polygonati all have human body immunity improving power, suppress the effect of tumor cell proliferation, can further improve the eliminating evil effect of strengthening the body resistance of the present invention thus.
Taste are become estranged and further medicament curative effect enhancement due to the cold medicine, preferably add Rhizoma Zingiberis 1-15 part in above-mentioned prescription.Also can select for use Fructus Piperis Longi or Rhizoma Alpiniae Officinarum 1-15 part to substitute Rhizoma Zingiberis.
Pharmaceutical composition of the present invention is formulation method routinely, is prepared into dosage forms such as capsule, tablet, powder, pill, granule, powder, mixture, oral liquid.
The trade name of medicine capsule of the present invention also is called the winter dragon capsule of choking of dispelling.
The usage and dosage of medicine of the present invention is: the extract meter of extracting method preparation routinely, and adult's oral medication, every day 2-3 time, 500--2000mg at every turn, three months is a course of treatment.The clinicist also can determine the usage and dosage of medicine according to patient's concrete condition.
Drug main of the present invention will be used for the treatment of the advanced esophageal carcinoma patient, also can be used for the inspection of esophageal carcinoma kinds of tumors mark, index positive person, such as: the treatment of TSGF, CEA, CA199, HCG, CA153 etc.
Medicine of the present invention should be noted during use: this product must be taken under the doctor instructs; Liver, renal function serious hindrance person and gestation or women breast-feeding their children, child use careful usefulness; The person of doing not feel like oneself in the process of taking, withdrawal immediately, and timely Ref Dr; Individual patients can be irritated, as the allergy of taking medicine can be stopped using;
This product can be used for esophageal carcinoma operation back after treatment; Can be used for performing the operation before preceding treatment, the chemotherapy, the treatment after the chemotherapy; Treatment before the radiotherapy, in the radiotherapy, after the radiotherapy; Can be used for preventing cancer return, the anti-treatment of shifting; Can be used for esophageal epithelial proliferation patient's treatment.
Beneficial effect of the present invention has obtained further checking by following test:
One, medicine of the present invention is to the inhibitory action of animal transplanting tumor growth:
Claimed by the reagent name:
Pharmaceutical composition of the present invention, i.e. embodiment 1,2,3 made medicines, be called successively in test the winter dragon dispel choke capsule I number, the winter dragon dispel and choke capsule II number: the winter dragon dispel and choke capsule III number.Provide by Shijiazhuang China light traditional Chinese medical science tumour hospital.Lot number is respectively: 20070618,20070619,20070620.Character: brown to chocolate brown powder, specification: 0.5g/ grain, preparation: be mixed with desired concn with distilled water.
The matched group medicine:
Ring phosphorus phthalein amine (CTX): Hengrui Medicine Co., Ltd., Jiangsu Prov. produces, lot number: 07020121 character: white crystals, specification: 200mg/ bottle, preparation: dilute with sterile saline.
PINGXIAO JIA0NANG (composition: Radix Curcumae, Semen Strychni Pulveratum, Herba Agrimoniae, Oletum Trogopterori, Alumen, Sal Nitri, dried knee joint (system), Fructus Aurantii, parched with bran), Xi'an Zhengda Pharmaceutical Co., Ltd. produces.Lot number: 070317.Specification: 0.23g/ grain, preparation: be mixed with desired concn with distilled water.
Animal subject:
Kunming mouse, sex: male and female dual-purpose, every batch of same sex of test.Body weight: 18～22g.Source: provide by Hebei province's Experimental Animal Center.The permission quality certification number: SCXK (Ji) 2003-1-003.Every treated animal number: 10.
Transplanted tumor mice: S
180Sarcoma, U
14Solid tumor, ascitic type goes down to posterity, and the Chinese department of Chinese medicine Chinese medicine Tang Shi of institute of institute Chinese medicine research center provides.
Test method:
Get well-grown S
180And U
14Solid tumor ascites is with 1: 4 dilution back of normal saline (cell concentration about 1～2 * 10
6Individual/mL), and inoculation respectively, every mice axil subcutaneous vaccination 0.2mL, random packet is established following 6 groups: (1) blank group; (2) positive controls 1:CTX (20mg/kg, lumbar injection 7 days); (3) positive controls 2: PINGXIAO JIA0NANG (0.77g/kg, gastric infusion 7 days); (4) test group 1: winter dragon choke capsule I number (3.3g/kg, the gastric infusion 7 days) of dispelling; (5) test group 2: winter dragon choke capsule II number (3.3g/kg, the gastric infusion 7 days) of dispelling; (6) test group 3: winter dragon choke capsule III number (3.3g/kg, the gastric infusion 7 days) of dispelling.Inoculation rises by above scheme and begin administration next day, and successive administration 7 days, administration volume are the 0.4mL/20g body weight.Administration finishes back 24h and takes off neck execution animal, and behind the title the weight of animals, dissection is got the tumor piece and weighed, and calculates tumour inhibiting rate according to following formula:
Result of the test sees table 1, table 2 for details.
Table 1: capsule of the present invention is to mice S
180The inhibitory action of transplanted tumor growth
As can be seen from Table 1, medicine of the present invention is to mice S
180The growth of sarcoma has the obvious suppression effect.More than experiment is carried out 3 times altogether, and the tumour inhibiting rate % of test group 1, test group 2, test group 3 is respectively 47.29,49.35,61.88 in the three batches of experiments; 50.20,54.04,60.61; 48.91,52.53,59.22.
Statistical results show, difference highly significant (P＜0.01) between the tumor-inhibiting action of each group of the present invention and the blank group.Its effect is better than positive controls 2 near positive controls 1.Three batches of experimental result repeatability are good.
Table 2 capsule of the present invention is to mice U
14The inhibitory action of transplanted tumor growth
As can be seen from Table 1, medicine of the present invention is to mice U
14The growth of solid tumor has the obvious suppression effect.More than experiment is carried out 3 times altogether, and to be respectively be 54.17,57.90,66.67 to the tumour inhibiting rate % of test group 1, test group 2, test group 3 in the three batches of experiments; 55.77,58.92,67.59; 55.89,58.08,65.29.
Statistical results show, difference highly significant (P＜0.01 between the tumor-inhibiting action of each group of the present invention and the blank group.Effect is better than positive controls 2 near positive controls 1.Three batches of experimental result repeatability are good.
Two, medicine of the present invention is to transplanting in the inhibitory action of the human body esophageal carcinoma Eca109 of nude mice growth
Be subjected to the reagent thing identical with above-mentioned test; The positive controls medicine is identical with positive controls 2 used medicines in the above-mentioned test.
Animal subject: BALB/C nude mice (SPF level); Sex: female, every batch of same sex of test.Body weight: 16～19g source: Tumour Inst., Chinese Medical Academy; The permission quality certification number: SYXK 11-00-0012; Every treated animal number: 10.
Transplanted tumor: human body esophageal carcinoma Eca109, Tumour Inst., Chinese Medical Academy provides.
Test method:
Get well-grown Eca109 tumor piece, prepare into about 6 * 10 with normal saline homogenate
6The cell suspension of individual/mL cell concentration, every mice axil subcutaneous vaccination 0.2mL, random packet is established following 5 groups: (1) blank group; (2) positive controls 2: PINGXIAO JIA0NANG (0.77g/kg, gastric infusion 10 days); (3) test group 1: winter dragon choke capsule I number (3.3g/kg, the gastric infusion 10 days) of dispelling; (4) test group 2: winter dragon choke capsule II number (3.3g/kg, the gastric infusion 10 days) of dispelling; (5) test group 3: winter dragon choke capsule III number (3.3g/kg, the gastric infusion 10 days) of dispelling.Inoculate back 7 days all animals inoculation position visible one little lumps, begin administration by above scheme, successive administration 10 days, administration volume are the 0.5mL/20g body weight.Calculated gross tumor volume (v=ab with slide gauge survey tumor block length footpath (a) and minor axis (b) in per 3 days
2/ 2).The inoculation back was taken off neck on the 18th～20 and is put to death animal, and behind the title the weight of animals, dissection is got the tumor piece and weighed, and calculates tumour inhibiting rate according to following formula:
More than experiment is carried out 2 times altogether.
Result of the test is seen: table 3.
Table 3 capsule of the present invention is to transplanting in the inhibitory action of the human body esophageal carcinoma Eca109 of nude mice growth
Capsule oral administration of the present invention has the obvious suppression effect to transplanting in the human body esophageal carcinoma Eca109 of nude mice growth, the tumour inhibiting rate % of test group 1, test group 2, test group 3 is respectively 72.16,75.98,83.82 in the two batches of experiments, 75.54,77.49,84.29, two batches of experimental results repeatability is good.
Statistical results show, of the present invention group has the obvious suppression effect to transplanting in the human body esophageal carcinoma Eca109 of nude mice growth, difference highly significant between its tumor-inhibiting action and the blank group, effect is better than positive controls.
Three, capsule of the present invention cooperates the clinical effectiveness of radiotherapy in the treatment late esophagus cancer:
Clinical data
Ordinary circumstance: divide treatment group, matched group, two groups of totally 60 routine late esophagus cancer patients.Male's 14 examples in the treatment group, women's 16 examples, the age, the mean age was 65.5 years old from 50-76 year.Male's 19 examples in the matched group, women's 11 examples, the age, the mean age was 64.5 years old from 45-83 year.Two groups of cases do not have significant difference in ordinary circumstances such as sex, ages.
Diagnostic criteria: 60 routine patients are late esophagus cancer (length of lesion 〉=5 centimetre) patient, and clear and definite esophagogram diagnosis or pathological diagnosis are all arranged.
Include standard in:
1. diagnosis clear and definite (be the late esophagus cancer patient, length of lesion 〉=5 centimetre) meets diagnostic criteria.
2. the age is at 45-85 between year.3. estimate life cycle 〉=3 month.4. the Ka Shi scoring is 〉=30 minutes.
Exclusion standard:
1. early metaphase esophageal carcinoma patient, the patient of length of lesion＜5 centimetre.
2. there are the interventional therapy of cooperation, gamma knife treatment, operative treatment or other cancer drug therapy person all not to charge to this group case during the treatment.
3. the age is person below 45 years old or more than 85 years old.
4. be associated with severe cardiac, brain, liver, kidney disease and can not adhere to therapist.
5. do not take medicine the incomplete or therapy discontinued person of data in accordance with regulations.
Experimental technique:
Grouping: observe 60 examples altogether, adopting year July in June, 2004-2007 mixture of the present invention (embodiment 4 made medicines) to cooperate the case of Co-60 radiotherapy is treatment group case, and the simple Co-60 radiotherapy of the case before in June, 2004 is so be the matched group case.
Dosage regimen:
1. treatment group: concrete medication is: mixture of the present invention (embodiment 4 is made), each 1 bag, every day 3 times.Points for attention are the irritable food that avoids pungent food, and avoid tobacco and wine.Capable simultaneously Co-60 radical radiation therapy, single dose: 2Gy, accumulated dose 60Gy, 30 times.
2. matched group: go the Co-60 radical radiation therapy merely, scheme is with the treatment group.
3. course of treatment: all patients are 1 course of treatment with one and a half months.
Estimate effectiveness and safety observation index:
Health giving quality observation:
Alleviate fully (CR): X ray esophagus canel barium meal contrast examination X ray is levied disappearance, the basic recovery normally.The sign that the no tumor of physical examination (abbreviation health check-up) exists was above one month.
Part is alleviated (PR): X ray esophagus canel barium meal contrast examination and health check-up can be measured tumor and be dwindled more than 50%, do not have new focus and occur, and continue above 1 month.
Little effect (MR): X ray esophagus canel barium meal contrast examination and health check-up can be measured tumor and be dwindled more than 25%, but less than 50% does not have new focus appearance, continues above one month.
Stable (SD): X ray esophagus canel barium meal contrast examination and health check-up can be measured tumor and be dwindled less than 25%, increase less than 25%, continue above 1 month.
Progress (PD): X ray esophagus canel barium meal contrast examination and health check-up can be measured tumor and be increased more than 25%, or have new focus to occur.
Safety observation: just conventional (3) hepatic and renal function (4) electrocardiogram of (1) general physical examination (2) hematuria.
Life quality (Kamofsky) evaluation criteria: 100 fens energy normal activities.80-90 divides needs special care.50-70 divides cisco unity malfunction, can live at home, and most lives can be taken care of oneself, and need help in various degree.The 0-40 branch be can't take care of oneself, and needs the nursing of hospital or corresponding mechanism, and the state of an illness may worsen rapidly.
Improve: increase 〉=10 fens before the treatment of treatment back scoring ratio; Reduce: reduce 〉=10 fens before the treatment of treatment back scoring ratio; Stablize: compare increase before scoring of treatment back and the treatment or reduce less than 10 minutes.
Experimental result:
The treatment group can be estimated case 30 examples, and matched group can be estimated case 30 examples.
Treatment is organized in 30 examples, CR21 example wherein, PR7 example, MR0 example, SD0 example, PD0 example.CR+PR＝21+9/30＝100％。CR1 example in the matched group, PR15 example, MR2 example, SD5 example, PD7 example, CR+PR=16/30=53%.Treatment group obvious effective rate is apparently higher than matched group.Compare P＜0.01 with matched group.See table 4 for details.
Table 4;
| Effective case 60 examples | CR | PR | MR | SD | PD |
| 30 examples are organized in treatment | 21 | 9 | 0 | 0 | 0 |
| Matched group 30 examples | 1 | 15 | 2 | 5 | 7 |
Toxicity: the treatment group is not seen reactions such as tangible gastrointestinal reaction, hepatic and renal function injure, leukopenia, electrocardiographic abnormality before and after treatment.
The variation of quality of life before and after the treatment: see table 5 for details.
Table 5
| Grouping | n | Improve | Stable | Descend | Improve coefficient of stabilization (%) |
| The treatment group | 30 examples | 25 | 5 | 0 | 100％ |
| Matched group | 30 examples | 14 | 5 | 11 | 63％ |
This shows that toxic and side effects of the present invention is little, and can obviously improve anticancer therapeutic, improve patient's life quality.
The specific embodiment
The following examples can illustrate in greater detail the present invention, but do not limit the present invention in any form.
Embodiment 1
Take by weighing Rabdosia rubescens 120g, Gekko Swinhonis 25g, Radix Sophorae Tonkinensis 25g, Rhizoma Pinelliae Preparatum 5g, Rhizoma Arisaematis (processed) 10g, Radix Ginseng Rubra 30g, Semen Astragali Complanati 25g, Radix Scutellariae 30g.
With above-mentioned medical material ethanol percolate extraction, reclaim ethanol, according to conventional method concentrate drying extract.The gained dry extract is pulverized, and mixing is made capsule.0.5g/ grain.
Embodiment 2
Take by weighing Rabdosia rubescens 100g, Gekko Swinhonis 30g, Radix Sophorae Tonkinensis 25g, Rhizoma Pinelliae Preparatum 5g, Rhizoma Arisaematis (processed) 10g, Radix Ginseng Rubra 30g, Semen Astragali Complanati 30g, Radix Scutellariae 20g, Lentinus Edodes 20g, Radix Astragali 15g.
Said medicine is ground into coarse powder, adds 70～75% alcohol reflux 2 times of 8～10 times of amounts, each 1～1.5 hour, filter, merging filtrate, decompression filtrate recycling ethanol, concentrated extracting solution further concentrates, is dried to dried cream with concentrated solution, pulverize, mixing is made capsule.0.5g/ grain.
Embodiment 3
Take by weighing Rabdosia rubescens 8g, Gekko Swinhonis 25g, Radix Sophorae Tonkinensis 30g, Rhizoma Pinelliae Preparatum 10g, Rhizoma Arisaematis (processed) 10g, Radix Ginseng Rubra 30g, Semen Astragali Complanati 25g, Radix Scutellariae 30g, Lentinus Edodes 30g, Radix Astragali 25g, Rhizoma Zingiberis 10g.
Be prepared into capsule according to embodiment 2 described methods.0.5g/ grain.
The mixture of embodiment 4 pharmaceutical compositions of the present invention
With extracting solution prepared among the embodiment 2, add distilled water to 1000ml, be distributed into every bag of 100ml.
Embodiment 5
Prepare tablet according to methods known in the art, every contains following compositions:
Prepared dry extract 200mg among the embodiment 1
Starch 70mg
Magnesium stearate 3mg
Embodiment 6～8
According to preparation method known in the art, make oral formulations such as oral liquid, capsule and soft capsule, the proportioning weight of each component is as follows:
Above example of formulations, just the proportioning and the dosage form of drug component are different, but all have effect of the present invention.
Claims (6)
1. pharmaceutical composition that is used for the treatment of late esophagus cancer is characterized in that it comprises the raw material of following weight part ratio:
Rabdosia rubescens 20-120 part, Gekko Swinhonis 20-40 part, Radix Sophorae Tonkinensis 25-35 part, Rhizoma Pinelliae Preparatum 5-15 part, Rhizoma Arisaematis (processed) 5-15 part, Radix Ginseng Rubra 15-30 part, Semen Astragali Complanati 20-30 part, Radix Scutellariae 20-30 part.
2. pharmaceutical composition according to claim 1 is characterized in that it comprises the raw material of following weight part ratio:
Rabdosia rubescens 80-120 part, Gekko Swinhonis 25-30 part, Radix Sophorae Tonkinensis 25-35 part, Rhizoma Pinelliae Preparatum 5-10 part, Rhizoma Arisaematis (processed) 5-10 part, Radix Ginseng Rubra 20-30 part, Semen Astragali Complanati 25-30 part, Radix Scutellariae 20-30 part.
3. a pharmaceutical composition according to claim 1 and 2 is characterized in that it also includes the raw material of following weight part ratio: Lentinus Edodes 20-30 part, Radix Astragali 15-25 part.
4. a pharmaceutical composition according to claim 1 and 2 is characterized in that it also includes the raw material of following weight part ratio: Ganoderma spore oil 20-30 part, Fructus Lycii 15-25 part, Rhizoma Polygonati 20-30 part.
5. a pharmaceutical composition according to claim 1 and 2 is characterized in that it also includes the raw material of following weight part ratio: Rhizoma Zingiberis or Fructus Piperis Longi or Rhizoma Alpiniae Officinarum 1-15 part.
6. a pharmaceutical composition according to claim 3 is characterized in that it also includes the raw material of following weight part ratio: Rhizoma Zingiberis 1-15 part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101394458A CN101391004B (en) | 2007-09-18 | 2007-09-18 | Medicine composition for treating late-stage esophageal carcinoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101394458A CN101391004B (en) | 2007-09-18 | 2007-09-18 | Medicine composition for treating late-stage esophageal carcinoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101391004A CN101391004A (en) | 2009-03-25 |
| CN101391004B true CN101391004B (en) | 2010-12-01 |
Family
ID=40491645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007101394458A Expired - Fee Related CN101391004B (en) | 2007-09-18 | 2007-09-18 | Medicine composition for treating late-stage esophageal carcinoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101391004B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103315304A (en) * | 2012-07-28 | 2013-09-25 | 赵振华 | Rabdosia rubescens Chinese herbal beverage and preparation method thereof |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101700382B (en) * | 2009-11-12 | 2014-12-10 | 张国营 | Cancer pain elimination pill |
| CN105853604A (en) * | 2016-05-11 | 2016-08-17 | 张士舜 | Traditional Chinese medicinal composition for treating esophagus cancer and preparation method of traditional Chinese medicinal composition |
| CN107582961A (en) * | 2016-07-09 | 2018-01-16 | 朱智文 | Early stage esophageal squamous cell carcinoma electuary and its formula |
-
2007
- 2007-09-18 CN CN2007101394458A patent/CN101391004B/en not_active Expired - Fee Related
Non-Patent Citations (4)
| Title |
|---|
| 叶加等.食管癌中医及中西医结合临床治疗进展.《中医杂志》.2000,第41卷(第11期),693-695. * |
| 杨振江等.食管癌的中医药治疗概况.《中医药信息》.1993,(第4期),16-20. * |
| 赵付芝等.生半夏生胆南星为主治疗食管癌.《山东中医杂志》.1999,第18卷(第12期),546-547. * |
| 郭春华等.中医药在食管癌治疗中的应用概况.《江苏中医药》.2005,第26卷(第2期),59-61. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103315304A (en) * | 2012-07-28 | 2013-09-25 | 赵振华 | Rabdosia rubescens Chinese herbal beverage and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101391004A (en) | 2009-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101491663B (en) | Traditional Chinese medicine composition for treating various cancer | |
| CN100490789C (en) | Enteric coated Chinese medicinal capsule for treating cancer and preparation method thereof | |
| CN101716280B (en) | Medicine composite used for curing liver cancer | |
| CN104352608B (en) | A kind of benefiting QI for activating blood circulation, hard masses softening and resolving, the Chinese medicine and preparation method thereof of removing toxic substances pain relieving | |
| CN102008650B (en) | Compound traditional Chinese medicine preparation for treating tumors and preparation method thereof | |
| CN101391004B (en) | Medicine composition for treating late-stage esophageal carcinoma | |
| CN102861193B (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| CN101091769B (en) | Medicine for treating and preventing esophagus cancer and gastric cancer, and preparation method | |
| CN104055935B (en) | It is a kind of to cooperate with the Chinese medicine composition for improving immunity | |
| CN102028924B (en) | Medicinal composition for late gastric cancer | |
| CN108186794B (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method and application thereof | |
| CN103933450A (en) | Traditional Chinese medicine composition for preventing or/and treating gastrointestinal diseases and preparation method of composition | |
| CN103550718B (en) | A kind of Chinese medicine composition for the treatment of pulmonary carcinoma | |
| CN100464759C (en) | Anticancer Chinese traditional extracts and preparation process and application thereof | |
| CN1225258C (en) | Chinese medicine compound preparation for curing pancreatic cancer | |
| CN102908443B (en) | Medicinal composition for therapy or adjuvant therapy of aids, preparation method of medicinal composition and application of medicinal composition | |
| CN104127757A (en) | Traditional Chinese medicinal composition having body resistance strengthening and yin nourishing effects, and preparation method and application thereof | |
| CN103948859A (en) | Anti-tumor traditional Chinese medicine compound preparation as well as preparation method and application thereof | |
| CN102836315A (en) | Chinese medicinal composition for preventing and conditioning prognosis tumors and preparation method thereof | |
| CN1194717C (en) | Snake poison capsule for treating lung cancer and its preparation method | |
| CN101259180A (en) | Shenshe composition and preparation thereof | |
| CN101229272A (en) | Medicine compounds for increasing immunizing-power, preparing method and applications thereof | |
| CN104689246B (en) | A kind of medicine for the treatment of gastric cancer | |
| CN104398704A (en) | Traditional Chinese medicine composition for treating stomach cancer and preparation method thereof | |
| CN104189846A (en) | Traditional Chinese medicine composition used as radiotherapy and chemotherapy sensitizing agent and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101201 Termination date: 20140918 |
|
| EXPY | Termination of patent right or utility model |